Safety of new biologic therapies in rheumatoid arthritis

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

The common side effects associated with the use of TNF inhibitors are mild, well tolerated, self-limiting, and seldom enough of a nuisance to warrant discontinuation. The benefit-to-risk ratio for the anticytokine therapies appears to be very favorable for patients with aggressive RA. Serious and potentially life threatening adverse events are rare, even in the postmarketing era. As many of these serious toxicities occur at rates of < 1 case per 1,000 patient years of TNF inhibitor use, it appears that proper patient selection and prevention measures may limit this risk further.

Original languageEnglish (US)
JournalBulletin on the Rheumatic Diseases
Volume52
Issue number8
StatePublished - Dec 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Safety of new biologic therapies in rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this